Few drugs have had a stranger arc through American medicine than droperidol. For thirty years it was a workhorse — used in operating rooms for nausea, in emergency departments for acute agitation and migraine, and occasionally in psychiatric settings as a fast-acting antipsychotic. Then, in 2001, the FDA added a black box warning about cardiac risk that effectively pushed the drug out of routine use. Two decades later, with a clearer view of the actual risk, droperidol has been quietly making a comeback in emergency medicine.
Droperidol is a fast-acting butyrophenone antipsychotic with a complicated FDA history that limited its use for years — and a growing emergency medicine literature suggesting that, used appropriately, the cardiac risk is much smaller than initially feared.
What droperidol is
Droperidol is a butyrophenone — chemically related to haloperidol — that blocks dopamine D2 receptors and also has anti-nausea (anti-emetic) effects. It is given intramuscularly or intravenously, almost never orally, and has a faster onset and shorter duration than haloperidol. Onset is within 5–10 minutes, peak effect at 20–30 minutes, and clinical effect typically lasts 2–4 hours.
The original uses
Through the 1980s and 1990s, droperidol had three main roles:
- Acute agitation — particularly in emergency departments, often given IM with or without lorazepam
- Postoperative and chemotherapy-induced nausea — given IV in low doses
- Migraine — used as a rescue treatment for severe headaches not responding to standard care
Many emergency physicians who trained in that era describe droperidol as a remarkably effective drug — fast, reliable, and well-tolerated when dosed appropriately.
The 2001 black box warning
In 2001 the FDA strengthened the droperidol label to include a boxed warning about QT prolongation and torsades de pointes, citing post-marketing reports of cardiac arrhythmias and sudden death. The warning recommended a 12-lead ECG before administration, continuous cardiac monitoring during and for 2–3 hours after dosing, and use only when other treatments had failed. In effect, the warning made routine emergency use impractical.
The decision was controversial at the time and has remained so. Many of the cited cases involved very high doses (well above those used for agitation), pre-existing cardiac disease, or concurrent QT-prolonging medications. The warning made no clear distinction between the small doses used for nausea and the larger doses used in some surgical contexts.
The comeback
In the years since, multiple emergency-medicine studies have re-examined droperidol's safety profile at the doses actually used for agitation and nausea. The consensus from this newer literature, summarised by the American Academy of Emergency Medicine in 2014 and again in updated reviews, is that low-dose droperidol (≤2.5 mg IV or IM for nausea, up to 5–10 mg IM for agitation) carries minimal cardiac risk in patients without specific risk factors. Based on this, many emergency departments have re-incorporated droperidol into their agitation and headache protocols. The black box remains on the label.
Where droperidol is used today
- Acute agitation in the emergency department — often as a single dose, sometimes with a benzodiazepine
- Severe headache and migraine — as rescue treatment
- Postoperative nausea and vomiting — at very low doses
- Less commonly in inpatient psychiatry — for selected acute agitation when other agents are inappropriate
How it is dosed (illustrative ranges)
Specific dosing is always determined by the prescribing clinician. Typical ranges in the literature:
- Agitation: 2.5–10 mg IM, sometimes repeated once
- Nausea: 0.625–1.25 mg IV
- Headache: 2.5–5 mg IM or IV
Side effects
Cardiovascular
QT prolongation is the headline risk and the reason for the boxed warning. Risk is greater at higher doses, in patients with electrolyte abnormalities (low potassium, low magnesium), in patients on other QT-prolonging drugs, and in patients with structural heart disease or prior arrhythmia. Modern protocols typically include a baseline ECG when feasible and avoid use in patients with significant risk factors.
EPS and dystonia
As a butyrophenone, droperidol can cause acute dystonia and akathisia. Risk is similar to haloperidol at equivalent doses.
Sedation
Mild to moderate sedation is common and often clinically useful in agitation contexts.
Hypotension
Possible, particularly with rapid IV administration in volume-depleted patients.
Neuroleptic malignant syndrome
Rare; see our NMS article.
The patient has known long QT syndrome, recent significant electrolyte derangements, severe heart disease, or is on multiple other QT-prolonging medications. In these settings, an alternative is usually safer.
Where droperidol does not fit
- Outpatient maintenance treatment of schizophrenia (it is not used this way)
- Patients with congenital long QT syndrome
- Patients on multiple QT-prolonging drugs without clear benefit
Practical context for patients and families
If you or a loved one receives droperidol in an emergency department, the team is using it because it works fast for agitation, nausea, or migraine. The cardiac risk, while real and worth knowing about, is small at the doses used. Tell the team about any prior cardiac issues, prior bad reactions to haloperidol, current medications, and any history of involuntary movements or stiffness on similar drugs. That information shapes the safest choice in the moment.
The big picture
Droperidol is a story about what happens when a single regulatory action redefines a drug. For two decades, a useful, well-known medication was largely shelved on the basis of warnings that subsequent evidence has substantially qualified. The drug is back, in measured ways, and many emergency physicians are glad to have it. As always, the right tool depends on the patient, the setting, and the clinician using it. Droperidol is now part of that toolkit again — used carefully, in selected situations, by teams who know it well.
This article is for educational purposes only and is not medical advice. Information is summarised from publicly available FDA labelling and peer-reviewed literature. Always consult your prescribing clinician before starting, stopping, or changing any medication.